Dren Bio

Dren Bio

  • Founded: 2019
  • Location: Foster City, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Blood cancers
  • Drug types: ONC, IMM
  • Lead product: DR-01
  • Product link: https://www.drenbio.com/pipeline.html
  • Funding: $65M B Jun 2022; $60M A Oct 2020
  • Investors: Aisling Capital, HBM Healthcare Investments, Pfizer, ArrowMark Partners, Revelation Partners, SR One, 8VC, Taiho Ventures, BVF Partners, Mission BioCapital, Alexandria Venture Investments



job board

Short description:

Protein Therapeutics

Drug notes:

Also Clin0 autoimmune disease; DR-0201 Clin0 B-cell malignancies; DR-02 3 efforts RD/Clin0 solid tumors, RD light chain amyloidosis

Long description:

Dren Bio is using protein engineering technologies to develop therapeutic antibodies for cancer and autoimmune diseases. Current research suggests that many diseases can be treated if the relevant elements of the immune system can be activated. Dren’s approach is to selectively engage and deplete pathologic cells, protein aggregates or other disease-causing agents, by designing engineered antibodies. Their pipeline currently has two distinct programs. Dren’s lead program, DR-01, falls under their antibody-dependent cellular cytotoxicity program for antibody mediated killing of target cells. Their second program, Targeted Myeloid Engager and Phagocytosis Platform, uses Dren’s proprietary bispecific antibodies to engage both immune and cancer cells to support durable anti-tumor immune responses.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com